# A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

> **NCT05281328** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Camurus AB** · enrollment: 71 (actual)

## Conditions studied

- Polycystic Liver Disease

## Interventions

- **DRUG:** CAM2029
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05281328
- **Lead sponsor:** Camurus AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-28
- **Primary completion:** 2025-02-05
- **Final completion:** 2027-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281328, "A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05281328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*